656.84
-7.93 (-1.19%)
| Previous Close | 664.77 |
| Volume | 142,179 |
| Price / Earnings (Forward) | 33.71 |
| Price / Sales | 6.73 |
| Price / Book | 31.78 |
| 52 Weeks Range |
| Profit Margin | 19.31% |
| Operating Margin (TTM) | 20.32% |
| Diluted EPS (TTM) | 13.10 |
| Quarterly Revenue Growth (YOY) | 9.30% |
| Quarterly Earnings Growth (YOY) | 11.70% |
| Total Debt/Equity (MRQ) | 25.33% |
| Current Ratio (MRQ) | 0.730 |
| Operating Cash Flow (TTM) | 581.97 M |
| Levered Free Cash Flow (TTM) | 433.28 M |
| Return on Assets (TTM) | 15.44% |
| Return on Equity (TTM) | 65.82% |
News Mood
AIStockmoo Score
| Value 30% | -0.5 |
| From our AI Insight report's view of expected return against risk. info | NA |
| Priced in line with its earnings growth. info | |
| The price implies earnings growth of 24.7% a year; the business can fund about 15.0% a year. info | |
| Valuation History info | NA |
| Low debt. Strong profitability. Thin short-term liquidity. Positive cash flow. info | |
| Return on Capital info | NA |
| Timing 30% | 2.3 |
| From our AI technical analysis of the chart. info | NA |
| No clear trend over the past year. Trading near its 52-week high. info | |
| Candle Patterns info | NA |
| Trend for Your Holding Period info | NA |
| Sentiment 20% | 0.6 |
| No recent price targets, so based on how targets have been revised. info | |
| Recent news mostly positive. info | |
| Smart Money 20% | 0.0 |
| Insiders net selling recently. info | |
| Institutional Flow info | NA |
| Short Interest info | NA |
| Market and sector conditions are favourable. | |
| Market environment cautious. info | |
| Sector outperforming the market. | |
| The pillars agree, so the score is strengthened. | |
| Not in score | |
| Price is high against its 52-week average. Up over 5 years. info | |
| Trend up on all three terms. Short-term momentum rising. info | |
| Price is between support and resistance. Levels trending up. info | |
| Final Score | 0.74 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Medpace Holdings, Inc. | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| MEDP | - | - | - | 31.78 |
| ILMN | - | - | - | 10.00 |
| NTRA | - | - | - | 24.64 |
| IDXX | - | - | - | 29.71 |
| GH | - | - | - | - |
| NEO | - | - | - | 2.58 |
Select this tab to load the latest available analysis.
|
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Growth |
| % Held by Insiders | 20.55% |
| % Held by Institutions | 91.47% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 11 Nov 2026 | Yahoo Finance |
3 Reasons Why Growth Investors Shouldn't Overlook Medpace (MEDP)
Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials. |
| 06 Nov 2026 | Yahoo Finance |
If You Invested $1000 in Medpace a Decade Ago, This is How Much It'd Be Worth Now
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards. |
| 05 Nov 2026 | Yahoo Finance |
Did Earnings Beat Just Shift Medpace Holdings (MEDP) Investment Narrative?
Medpace Holdings reported third quarter 2026 adjusted EPS of $4.84 and revenue of $716 million, both above Zacks consensus estimates. The combination of an earnings beat and an estimated 14.3% long-term earnings growth rate highlights how Medpace Holdings is executing against demand for outsourced… |
| 02 Nov 2026 | Yahoo Finance |
CON vs. MEDP: Which Stock Is the Better Value Option?
CON vs. MEDP: Which Stock Is the Better Value Option? |
| 30 Oct 2026 | Yahoo Finance |
2 high-flying stocks on our watchlist and 1 we turn down
Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices, leaving little room for error if they stumble even slightly. |
| 30 Oct 2026 | Yahoo Finance |
Medpace (MEDP) is a Great Momentum Stock: Should You Buy?
Does Medpace (MEDP) have what it takes to be a top stock pick for momentum investors? Let's find out. |
| 30 Oct 2026 | Yahoo Finance |
RMD Stock Up on Q1 Earnings and Revenue Beat, Gross Margin Climbs
ResMed's first-quarter fiscal 2027 earnings and revenues top estimates as sustained sleep device demand, productivity gains and gross margin expansion drive growth. |
| 29 Oct 2026 | Yahoo Finance |
Medpace Holdings, Inc. (MEDP) Hits Fresh High: Is There Still Room to Run?
Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. |
| 28 Oct 2026 | Yahoo Finance |
Breakout Watch: 4 Reasons To Monitor This Top-Rated Medical Stock
A best-possible 99 Composite Rating is just one reason to watch Medpace stock. Here are four more telltale clues to monitor. |
| 28 Oct 2026 | Yahoo Finance |
BSX Q3 Earnings Meet Estimates, Revenues Rise Y/Y, Stock Down
Boston Scientific's third-quarter revenues beat estimates, but contracting margins, weaker segment sales and reduced 2026 guidance weigh on shares. |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |